BioNTech's Oncology Bet Pays Off in Seoul as Analysts Race to Raise Targets
Published on 09/17/2026 at 08:01 | Editorial boerse-global.de
BioNTech picked an opportune moment to remind investors what its pipeline can do. In the same week that Novartis stumbled through two failed Phase 3 programs — a blunt illustration of how unforgiving drug development can be — the Mainz-based company delivered late-stage data that suggests its oncology pivot is more than a story.
At the World Conference on Lung Cancer (WCLC) in Seoul, BioNTech presented results for gotistobart, a CTLA-4 antibody developed with partner OncoC4 and also known as BNT316/ONC-392. In the Phase 3 PRESERVE-003 trial, the drug achieved a median overall survival of 18.5 months in patients with advanced squamous non-small cell lung cancer who had already undergone at least one prior therapy. The comparator arm, treated with standard docetaxel chemotherapy, managed just 10 months. The response rate came in at 20 percent versus 4.8 percent for chemotherapy, with a comparable tolerability profile. Gotistobart already carries Fast Track and Orphan Drug designations from the FDA.
Earlier-phase data had pointed the same direction. In the preceding Phase 1 study, the risk of death fell 54 percent relative to docetaxel, and median overall survival in the treatment group was never reached, while the control arm sat at 9.95 months. Those are the kind of numbers that keep a stock on the map even when the core business looks shaky.
A second asset draws attention
BioNTech also rolled out data on the combination of pumitamig and elfetabart in first-line small cell lung cancer. According to Berenberg, the duo posted a 92 percent response rate in first-line treatment, 76 percent in the second line, and still 52 percent among heavily pretreated patients. UBS analyst David Dai noted that no dose-limiting toxicities emerged, and the discontinuation rate stayed low at 3.9 percent.
The sell-side response was swift and uniform. Dai reaffirmed his Buy rating with a price target of 135 US dollars, pointing to an interim readout expected in 2026 and a possible regulatory filing in 2027. Jefferies analyst Akash Tewari also kept his Buy call and a 138-dollar target. Berenberg's Harry Gillis went furthest, lifting his target from 132 to 140 US dollars. Berenberg pegs the peak sales potential for pumitamig at 5 billion US dollars, assuming a 50 percent probability of success, and 3 billion for elfetabart. With that kind of pipeline math in play, the discontinued development of the colorectal cancer vaccine candidate iNeST fades further into the background of the investment case.
Should investors sell immediately? Or is it worth buying BioNTech?
Frankfurt shrugs while New York bids
The market's immediate reaction was oddly muted on home turf. The stock closed Wednesday at 83.60 euros in Frankfurt, 0.2 percent weaker than the previous day, hovering near its 50-day moving average of 84.21 euros and roughly 21 percent below the 52-week high of 105.80 euros set in January. The restrained Frankfurt session contrasted with a firmer showing in New York, where the shares gained more ground during US trading.
Competition in oncology remains fierce. Johnson & Johnson used the same conference to present new survival data for its RYBREVANT regimen in EGFR-mutated lung cancer, and OncoC4 separately secured FDA Fast Track status for another candidate, cesalatamig.
The operating business keeps shrinking
For all the clinical momentum, the commercial picture is deteriorating. First-half 2026 revenue fell to 223.7 million euros from 443.6 million a year earlier — the former Covid cash cow has become a sideshow. Full-year guidance sits between 1.6 and 1.9 billion euros. What cushions the transition is a liquidity position of 16.6 billion euros as of June 30, enough to fund the expensive build-out into an oncology company without needing fresh capital any time soon.
Insider activity has drawn some attention without rattling the market much. Since September 3, the CEO has sold a total of 289,000 shares, trimming his remaining stake of just over 553,000 shares by 2.64 percent. Such scheduled sales are routine among US executives and don't automatically signal a loss of confidence — though the timing, right as the study data should be providing tailwind, is notable.
Two valuation lenses, two conclusions
As with most biotech names carrying pipeline promise, the valuation debate splits cleanly. On a price-to-sales basis, BioNTech trades at roughly 7.9 times revenue, cheaper than the broader biotech sector at about 12.5 and the direct peer group at around 10.1. Substance-based models, by contrast, point to a higher fair value — a sign that the stock looks under- or overvalued depending on how much weight an investor gives the oncology pipeline today.
That is the real question hanging over the shares: is this still a company living off its vaccine legacy, or already an oncology specialist in the making? The PRESERVE-003 data argue for the latter; the shrinking top line and widening loss recall the former. Monthly performance shows a gain of 4.2 percent, and with an RSI just under 44, the technical picture suggests neither euphoria nor panic. Until those two narratives converge, the stock is likely to remain what it is right now — a name caught between two worlds, moved more by study readouts than by quarterly earnings.
Ad
BioNTech Stock: New Analysis - 17 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
